Retromuscular Mesh Repair of Midline Incisional Hernia Using Polyester Standard Mesh: Monocentric Experience of 261 Consecutive Patients With a 5-Year Follow-Up

D. Rosin

DOI: https://doi.org/10.1007/s00268-012-1478-3

IF: 3.282

2012-02-14

World Journal of Surgery

Abstract:

What problem does this paper attempt to address?

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

Anna Vaisman-Mentesh,Matias Gutierrez-Gonzalez,Brandon J. DeKosky,Yariv Wine

DOI: https://doi.org/10.3389/fimmu.2020.01951

IF: 7.3

2020-08-18

Frontiers in Immunology

Abstract:Monoclonal antibodies (mAbs) are a crucial asset for human health and modern medicine, however, the repeated administration of mAbs can be highly immunogenic. Drug immunogenicity manifests in the generation of anti-drug antibodies (ADAs), and some mAbs show immunogenicity in up to 70% of patients. ADAs can alter a drug's pharmacokinetic and pharmacodynamic properties, reducing drug efficacy. In more severe cases, ADAs can neutralize the drug's therapeutic effects or cause severe adverse events to the patient. While some contributing factors to ADA formation are known, the molecular mechanisms of how therapeutic mAbs elicit ADAs are not completely clear. Accurate ADA detection is necessary to provide clinicians with sufficient information for patient monitoring and clinical intervention. However, ADA assays present unique challenges because both the analyte and antigen are antibodies, so most assays are cumbersome, costly, time consuming, and lack standardization. This review will discuss aspects related to ADA formation following mAb drug administration. First, we will provide an overview of the prevalence of ADA formation and the available diagnostic tools for their detection. Next, we will review studies that support possible molecular mechanisms causing the formation of ADA. Finally, we will summarize recent approaches used to decrease the propensity of mAbs to induce ADAs.

immunology
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

Chantal T. Harris,Sivan Cohen

DOI: https://doi.org/10.1007/s40259-023-00641-2

IF: 7.744

2024-01-24

BioDrugs

Abstract:Monoclonal antibodies (mAbs) have transformed therapeutic strategies for various diseases. Their high specificity to target antigens makes them ideal therapeutic agents for certain diseases. However, a challenge to their application in clinical practice is their potential risk to induce unwanted immune response, termed immunogenicity. This challenge drives the continued efforts to deimmunize these protein therapeutics while maintaining their pharmacokinetic properties and therapeutic efficacy. Because mAbs hold a central position in therapeutic strategies against an array of diseases, the importance of conducting comprehensive immunogenicity risk assessment during the drug development process cannot be overstated. Such assessment necessitates the employment of in silico, in vitro, and in vivo strategies to evaluate the immunogenicity risk of mAbs. Understanding the intricacies of the mechanisms that drive mAb immunogenicity is crucial to improving their therapeutic efficacy and safety and developing the most effective strategies to determine and mitigate their immunogenic risk. This review highlights recent advances in immunogenicity prediction strategies, with a focus on protein engineering strategies used throughout development to reduce immunogenicity.

oncology,pharmacology & pharmacy,immunology
Monoclonal antibodies: From magic bullet to precision weapon

Hassan Aboul-Ella,Asmaa Gohar,Aya Ahmed Ali,Lina M Ismail,Adham Ezz El-Regal Mahmoud,Walid F Elkhatib,Heba Aboul-Ella

DOI: https://doi.org/10.1186/s43556-024-00210-1

2024-10-11

Abstract:Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of 2023) to 2033 (679.03 billion USD expected by the end of 2033). Ever since the advent of hybridoma technology introduced in 1975, antibody-based therapeutics were realized using murine antibodies which further progressed into humanized and fully human antibodies, reducing the risk of immunogenicity. Some benefits of using mAbs over conventional drugs include a drastic reduction in the chances of adverse reactions, interactions between drugs, and targeting specific proteins. While antibodies are very efficient, their higher production costs impede the process of commercialization. However, their cost factor has been improved by developing biosimilar antibodies as affordable versions of therapeutic antibodies. Along with the recent advancements and innovations in antibody engineering have helped and will furtherly help to design bio-better antibodies with improved efficacy than the conventional ones. These novel mAb-based therapeutics are set to revolutionize existing drug therapies targeting a wide spectrum of diseases, thereby meeting several unmet medical needs. This review provides comprehensive insights into the current fundamental landscape of mAbs development and applications and the key factors influencing the future projections, advancement, and incorporation of such promising immunotherapeutic candidates as a confrontation approach against a wide list of diseases, with a rationalistic mentioning of any limitations facing this field.
The role of therapeutic antibodies in drug discovery

L.H. Stockwin,S. Holmes

DOI: https://doi.org/10.1042/bst0310433

2003-04-01

Biochemical Society Transactions

Abstract:The last 5 years have seen a major upturn in the fortune of therapeutic monoclonal antibodies (mAbs), with nine mAbs approved for clinical use during this period and more than 70 now in clinical trials beyond phase II. Sales are expected to reach $4 billion per annum worldwide in 2002 and $15 billion by 2010. This success can be related to the engineering of mouse mAbs into mouse/human chimaeric antibodies or humanized antibodies, which have had a major effect on immunogenicity, effector function and half-life. The issue of repeated antibody dosing at high levels with limited toxicity was essential for successful clinical applications. Emerging technologies (phage display, human antibody-engineered mice) have created a vast range of novel, antibody-based therapeutics, which specifically target clinical biomarkers of disease. Modified recombinant antibodies have been designed to be more cytotoxic (toxin delivery), to enhance effector functions (bivalent mAbs) and to be fused with enzymes for prodrug therapy and cancer treatment. Antibody fragments have also been engineered to retain specificity and have increased the penetrability of solid tumours (single-chain variable fragments). Radiolabelling of antibodies has now been shown to be effective for cancer imaging and targeting. This article focuses on developments in the design and clinical use of recombinant antibodies for cancer therapy.

biochemistry & molecular biology
Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy

Christopher Chung,Sagar B. Kudchodkar,Curtis N. Chung,Young K. Park,Ziyang Xu,Norbert Pardi,Mohamed Abdel-Mohsen,Kar Muthumani

DOI: https://doi.org/10.3390/antib12030046

2023-07-07

Antibodies

Abstract:Harnessing the immune system to combat disease has revolutionized medical treatment. Monoclonal antibodies (mAbs), in particular, have emerged as important immunotherapeutic agents with clinical relevance in treating a wide range of diseases, including allergies, autoimmune diseases, neurodegenerative disorders, cancer, and infectious diseases. These mAbs are developed from naturally occurring antibodies and target specific epitopes of single molecules, minimizing off-target effects. Antibodies can also be designed to target particular pathogens or modulate immune function by activating or suppressing certain pathways. Despite their benefit for patients, the production and administration of monoclonal antibody therapeutics are laborious, costly, and time-consuming. Administration often requires inpatient stays and repeated dosing to maintain therapeutic levels, limiting their use in underserved populations and developing countries. Researchers are developing alternate methods to deliver monoclonal antibodies, including synthetic nucleic acid-based delivery, to overcome these limitations. These methods allow for in vivo production of monoclonal antibodies, which would significantly reduce costs and simplify administration logistics. This review explores new methods for monoclonal antibody delivery, including synthetic nucleic acids, and their potential to increase the accessibility and utility of life-saving treatments for several diseases.
Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework

Jason H. Williams,Kai H. Liao,Donghua Yin,Xu Meng

DOI: https://doi.org/10.1208/s12248-024-00901-1

2024-03-09

The AAPS Journal

Abstract:The interpretation of immunogenicity results for a mAb product and prediction of its clinical consequences remain difficult, despite enormous advances in methodologies and efforts toward the best practice for consistent data generation and reporting. To this end, the contribution from the clinical pharmacology discipline has been largely limited to comparing descriptively the pharmacokinetic (PK) profiles by antidrug antibodies (ADA) status or testing the significance of ADA as a covariate in a population PK setting, similar to the practice for small-molecule drugs in investigating the effect of an intrinsic/extrinsic factor on the drug disposition. There is a need for a mAb disposition framework that captures the dynamics of ADA formation and drug's interactions with the ADA and target as parts of the drug distribution and elimination. Here we describe such a framework and examine it against the PK, ADA, and clinical response data from a phase 3 trial in patients treated with adalimumab. The proposed framework offered a generalized understanding of how the dose, target affinity, and drug/ADA analyte forms affects the manifestation of ADA response with regard to its detections and alterations of drug disposition and effectiveness. Furthermore, as an example, its utility for dose considerations was demonstrated through predicting for late-stage trials of a PCSK9 inhibitor in terms of development in ADA incidence and titers, and consequences on the drug disposition, interaction with target, and downstream lowering effect on LDL-C.

pharmacology & pharmacy
Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery

Rajaganapathy Kaliyaperumal,Srinivasan Ranganathan,Masilamani Krishnamoorthy,Vasanth Kumar Mohan,Senthilnathan Balaraman,Gowri Rajapandian,Ramalingam Sathiyasundar,Saravanan Ravindran

DOI: https://doi.org/10.2174/0126673878260516231017165459

Abstract:The development of Monoclonal antibodies (mAbs) has also allowed researchers to understand the complexity of diseases better and find new treatments for difficult-to-treat conditions. Using mAbs, researchers can identify and target specific molecules in the body involved in the disease process. This has allowed for a more targeted treatment approach, which has resulted in improved outcomes for many patients. This hypothesis has been the basis for the development of mAbs that can target an array of illnesses. In the past two decades, therapeutic mAbs have been developed to treat cancer, autoimmune diseases, cardiovascular diseases, and metabolic diseases. For instance, using mAbs has improved outcomes in treating rheumatoid arthritis, multiple sclerosis, and Crohn's disease. However, delivering mAbs in biological systems remains a significant challenge in drug delivery. This is due to their large size, low stability in circulation, and difficulties in achieving their desired action in the target cells. Monoclonal antibodies (mAbs) are an essential tool in biological systems, as they can be used to deliver drugs to specific cell types or tissues. Cloning methods of monoclonal antibody production have been developed to produce mAbs with therapeutic potential. Hence, the present review focused on the development and drug delivery of Monoclonal antibodies (mAbs) in biological systems, which includes cloning methods, various drug delivery technologies, formulation production technology, and its applications in multiple diseases were focused for this review.
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations

Ole Haagen Nielsen,Alexander Hammerhøj,Mark Andrew Ainsworth,John Gubatan,Geert D’Haens

DOI: https://doi.org/10.1007/s40265-024-02115-3

2024-11-16

Drugs

Abstract:The introduction of tumor necrosis factor inhibitors has led to a paradigm shift in the management of inflammatory bowel disease (IBD). The subsequent introduction of both anti-integrins and cytokine blockers has since expanded the biologic armamentarium. However, immunogenicity, defined as the production of anti-drug antibodies (ADAs) to the prescribed biopharmaceutical, means a significant fraction of patients exposed to biologic agents will experience a secondary loss of response to one or more of the drugs. In clinical settings, immunogenicity may be caused by several factors, both patient related (e.g., underlying chronic disease, systemic immune burden, including previous biologic therapy failure, and [epi]genetic background) and treatment related (e.g., dose and administration regimens, drug physical structure, photostability, temperature, and agitation). Here, we outline these elements in detail to enhance biopharmaceutical delivery and therapy for patients with IBD. Moreover, concurrent immunomodulator medication may reduce the risks of ADA generation, especially when using the chimeric drug infliximab. Summarizing the latest developments and knowledge in the field, this review aims to provide strategies to prevent ADA production and information on managing non-responsiveness or loss of response to biologics. Better understanding of the molecular mechanisms underlying the formation of ADAs and the critical factors influencing the immunogenicity of biopharmaceuticals may lead to improved health outcomes in the IBD community that may benefit both the individual patient and society through lower healthcare expenses.

pharmacology & pharmacy,toxicology
The history of monoclonal antibody development – Progress, remaining challenges and future innovations

Justin K.H. Liu

DOI: https://doi.org/10.1016/j.amsu.2014.09.001

2014-12-01

Annals of Medicine and Surgery

Abstract:As medicine progresses into a new era of personalised therapy, the use of monoclonal antibodies to treat a wide range of diseases lies at the heart of this new forefront. Since the licencing of the first monoclonal antibody for clinical use 30 years ago, the monoclonal antibody industry has expanded exponentially and is now valued at billions of dollars. With major advances in genetic sequencing and biomedical research, much research into monoclonal antibodies now focuses on identifying new targets for development and maximising their efficacy for use in clinical practice. However, a balance has to be struck with regards to reducing numbers of side-effects and overall economic cost, which arguably somewhat blighted their early clinical and commercial successes. Nowadays, there are approximately 30 monoclonal antibodies that have been approved for use in clinical practice with many more currently being tested in clinical trials. Some of the current major limitations include: the use of inefficient models for generation, a lack of efficacy and issues of cost-effectiveness. Some of the current research focuses on ways to improve the efficacy of existing monoclonal antibodies through optimising their effects and the addition of beneficial modifications. This review will focus on the history of monoclonal antibody development - how it has increasingly moved away from using laborious animal models to a more effective phage display system, some of the major drawbacks from a clinical and economical point of view and future innovations that are currently being researched to maximise their effectiveness for future clinical use.
Drug Development of Therapeutic Monoclonal Antibodies

Diane R. Mould,Bernd Meibohm

DOI: https://doi.org/10.1007/s40259-016-0181-6

IF: 7.744

2016-06-24

BioDrugs

Abstract:Monoclonal antibodies (MAbs) have become a substantial part of many pharmaceutical company portfolios. However, the development process of MAbs for clinical use is quite different than for small-molecule drugs. MAb development programs require careful interdisciplinary evaluations to ensure the pharmacology of both the MAb and the target antigen are well-understood. Selection of appropriate preclinical species must be carefully considered and the potential development of anti-drug antibodies (ADA) during these early studies can limit the value and complicate the performance and possible duration of preclinical studies. In human studies, many of the typical pharmacology studies such as renal or hepatic impairment evaluations may not be needed but the pharmacokinetics and pharmacodynamics of these agents is complex, often necessitating more comprehensive evaluation of clinical data and more complex bioanalytical assays than might be used for small molecules. This paper outlines concerns and strategies for development of MAbs from the early in vitro assessments needed through preclinical and clinical development. This review focuses on how to develop, submit, and comply with regulatory requirements for MAb therapeutics.

oncology,pharmacology & pharmacy,immunology
First aid for dentists.

R. Bunting

DOI: https://doi.org/10.14219/JADA.ARCHIVE.1953.0053

1953-03-01

Abstract:
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Paul J. Carter,Valerie Quarmby

DOI: https://doi.org/10.1038/s41573-024-01051-x

IF: 112.288

2024-10-20

Nature Reviews Drug Discovery

Abstract:Remarkable progress has been made in recent decades in engineering antibodies and other protein therapeutics, including enhancements to existing functions as well as the advent of novel molecules that confer biological activities previously unknown in nature. These protein therapeutics have brought major benefits to patients across multiple areas of medicine. One major ongoing challenge is that protein therapeutics can elicit unwanted immune responses (immunogenicity) in treated patients, including the generation of anti-drug antibodies. In rare and unpredictable cases, anti-drug antibodies can seriously compromise therapeutic safety and/or efficacy. Systematic deconvolution of this immunogenicity problem is confounded by the complexity of its many contributing factors and the inherent limitations of available experimental and computational methods. Nevertheless, continued progress with the assessment and mitigation of immunogenicity risk at the preclinical stage has the potential to reduce the incidence and severity of clinical immunogenicity events. This Review focuses on identifying key unsolved anti-drug antibody-related challenges and offers some pragmatic approaches towards addressing them. Examples are drawn mainly from antibodies, given that the majority of available clinical data are from this class of protein therapeutics. Plausible and seemingly tractable solutions are in sight for some immunogenicity problems, whereas other challenges will likely require completely new approaches.

pharmacology & pharmacy,biotechnology & applied microbiology
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview

Pieter Hindryckx,Gregor Novak,Niels Vande Casteele,Reena Khanna,Debby Laukens,Jairath Vipul,Brian G. Feagan

DOI: https://doi.org/10.1007/s40265-017-0693-5

2017-02-23

Drugs

Abstract:The introduction of biologic therapy has revolutionized the treatment of inflammatory bowel disease (IBD). However, like all therapeutic proteins, monoclonal antibodies have immunogenic potential which is influenced by multiple drug- and patient-related factors. The reported incidence of anti-drug antibodies (ADAs) towards biologic drugs in IBD varies greatly in the literature and depends not only on differences in sensitization but also on the assay methodology and the timepoint of measurement. Sensitization with formation of ADAs is associated with an increased risk of infusion reactions, accelerated drug clearance, and a loss of response (LOR) to drug. Recently, a greater understanding of the pharmacokinetics of therapeutic antibodies has led to the development of new strategies to reduce immunogenicity and more efficient use of these drugs. These preventive strategies include regular scheduled dosing with maintenance of stable therapeutic trough drug concentrations, and co-administration of an immunosuppressive. Sub-therapeutic drug concentrations with low levels of ADAs can generally be overcome with dose escalation, whereas the presence of high concentrations of ADAs requires a switch to another therapeutic agent.

pharmacology & pharmacy,toxicology
Opportunities and Challenges of Therapeutic Monoclonal Antibodies As Medical Countermeasures for Biodefense

Wei Gang Hu,Les P Nagata

DOI: https://doi.org/10.4172/2157-2526.1000149

2016-01-01

Journal of Bioterrorism & Biodefense

Abstract:Antibodies, naturally produced in the body as part of the immune response to infectious agents, can also be introduced artificially to treat infectious diseases. Advances in biotechnology in the last decades have made human or humanized monoclonal antibodies (mAbs) as therapeutics possible. These therapeutic mAbs currently enjoy unprecedented success and recognition of their potential. Unlike vaccines, therapeutic mAbs can confer instant and consistent protection against bio-threat agents when administered regardless of the recipient’s immune status. Therapeutic mAbs can be administered in higher levels than those elicited by vaccines, and thus provide a higher level of protection or treatment that is necessary in a biological attack where people are exposed to a higher exposure of agent concentration than that found in nature. Furthermore, therapeutic mAbs have substantial advantages over antimicrobial drugs, such as high specificity, low systemic toxicity, relatively long half-life, and no concerns over disrupting the body’s microbiome. Therapeutic mAbs can be used for both pre- and post-exposure protection; therefore, they have great value as effective medical countermeasures (MedCMs) against bio-threat agents. However, there are still some challenges to be overcome before therapeutic mAbs become ideal MedCMs against bio-threat agents. In this review, both opportunities and challenges in development of therapeutic mAbs are discussed.
Therapeutic Antibodies and Immunologic Conjugates

Konstantin Dobrenkov,Nai-Kong V. Cheung

DOI: https://doi.org/10.1016/b978-0-323-47674-4.00030-x

2020-01-01

Abstract:Anticancer therapy using monoclonal antibodies (mAbs) is a rapidly evolving treatment modality with major clinical impact. Their tumor selectivity enables precision, thereby minimizing side effects. Novel genetic engineering methods have produced multifunctional constructs, drug conjugates, radioimmunoconjugates, immunocytokines, immunotoxins, immunoenzymes, immunoliposomes, and bispecific immune effector cell engagers. In the last two decades, numerous clinical trials with naked and conjugated mAbs have demonstrated significant improvements in tumor response and survival for different malignancies, resulting in a rapid expansion of the antibody armamentarium worldwide. Immune checkpoint inhibitors (ICIs) and antibodies that modify the tumor microenvironment have further energized the entire field of immunotherapy. Although ICIs have dramatically changed the therapeutic landscape in melanoma and non–small cell lung cancers, they have added another dimension to the conventional approach of naked antibodies and antibody immunoconjugates. The integration of these different antibody-based approaches into the emerging fields in cellular therapy and small molecules and the revisiting of conventional chemotherapy should ultimately maximize the curative potential of these approaches. Even among antibodies, mAbs do not have overlapping mechanisms of action or toxicity profiles, allowing for further exploration of dose, schedule, and multimodality combinations, especially at the time of minimal residual disease. This chapter emphasizes the evolution of antibody therapy from seminal preclinical work to successful clinical trials that lead to drug approval.
Monoclonal Antibodies: Emergence, Present and Outlook

Ji Gao,Juan He,Qingwen Wang,Wanli Liu

DOI: https://doi.org/10.1360/tb-2020-0490

2020-01-01

Abstract:Monoclonal antibodies are of great use in research and clinic. The first monoclonal antibody production method, hybridoma technology, was marked in the paper "Continuous cultures of fused cells secreting antibody of predefined specificity" by Milstein and Kohler in 1975 in Nature. Based on that paper, we took a retrospective and forward look of this technique. In the early research of antibodies and B cells, the low specificity and bad reproductivity of polyclonal antibodies called for new methods to produce highly specific antibodies. Fortunately, the scientists encountered the key prerequisites of the hybridoma method: (1) Mouse multiple myeloma cell lines, which can secrete antibodies and infinitely reproduce in vitro; (2) SRBC (sheep red blood cell) plates that can screen the cells secreteing anti-SRBC antibodies; (3) proper cell fusion methods like Sendai virus and PEG. Based on all these materials and methods, Milstein and Kohler fused spleen cells of immunized mice with mouse myeloma cell line P3-X67Ag8 by inactivated Sendai virus and screened to clone the fused cells that can secrete anti-SRBC antibodies. They also used HAT medium to ensure that only fused cells from spleen cells and myeloma cells can survive. In this way, they obtained the immortal cells that can produce a single type of antibody with a predefined antigen-specificity, or say, hybridoma cells that can produce monoclonal antibodies. This powerful tool of hybridoma was quickly applied and improved. Milstein and Kohler were awarded the Nobel prize and Lasker award in 1984. Despite the great commercial potential of hybridoma in medication and science research, Milstein and Kohler did not patent the method, making it free to use by anyone in the world. The monoclonal antibodies produced by hybridoma were proved highly versatile in the laboratory. Besides great insights provided to us in basic immunology research, they become the indispensable tool to precisely qualify, quantify, and localize macromolecule in all fields of research. Fluorescence imaging, Western blotting, flow cytometry and microarray methods all make use of monoclonal antibodies. Upon chimera, humanized and human monoclonal antibody development, the application and success of monoclonal antibodies on the biopharma market are even greater. Monoclonal antibody medicines to treat cancer and autoimmune diseases are making billions of dollars every year. Notably, among these medicines, anti-PD-1 and anti-CTLA-4 are awarded Nobel prize in 2018 as anti-tumor immune checkpoint inhibitors. Monoclonal antibody medicines for contagious diseases like Ebola also shows advantages over others. For the new outbreak of COVID-19 around the world, monoclonal antibodies are also promising in offering new cures. Presently, the production of monoclonal antibodies is no longer solely dependent on hybridoma technology. Transgenic and recombinant DNA technology are creating new possibilities in this ever-growing field.
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

Murli Krishna,Steven G. Nadler

DOI: https://doi.org/10.3389/fimmu.2016.00021

IF: 7.3

2016-02-02

Frontiers in Immunology

Abstract:Biological molecules are increasingly becoming a part of the therapeutics portfolio that has been either recently approved for marketing or those that are in the pipeline of several biotech and pharmaceutical companies. This is largely based on their ability to be highly specific relative to small molecules. However, by virtue of being a large protein, and having a complex structure with structural variability arising from production using recombinant gene technology in cell lines, such therapeutics run the risk of being recognized as foreign by a host immune system. In the context of immune-mediated adverse effects that have been documented to biological drugs thus far, including infusion reactions, and the evolving therapeutic platforms in the pipeline that engineer different functional modules in a biotherapeutic, it is critical to understand the interplay of the adaptive and innate immune responses, the pathophysiology of immunogenicity to biological drugs in instances where there have been immune-mediated adverse clinical sequelae and address technical approaches for their laboratory evaluation. The current paradigm in immunogenicity evaluation has a tiered approach to the detection and characterization of anti-drug antibodies (ADAs) elicited in vivo to a biotherapeutic; alongside with the structural, biophysical, and molecular information of the therapeutic, these analytical assessments form the core of the immunogenicity risk assessment. However, many of the immune-mediated adverse effects attributed to ADAs require the formation of a drug/ADA immune complex (IC) intermediate that can have a variety of downstream effects. This review will focus on the activation of potential immunopathological pathways arising as a consequence of circulating as well as cell surface bound drug bearing ICs, risk factors that are intrinsic either to the therapeutic molecule or to the host that might predispose to IC-mediated effects, and review the recent literature on prevalence and intensity of established examples of type II and III hypersensitivity reactions that follow the administration of a biotherapeutic. Additionally, we propose methods for the study of immune parameters specific to the biology of ICs that could be of use in conjunction with the detection of ADAs in circulation.

immunology
Building better monoclonal antibody-based therapeutics

George J. Weiner

DOI: https://doi.org/10.1038/nrc3930

IF: 78.5

2015-05-22

Nature Reviews Cancer

Abstract:Key PointsMonoclonal antibody (mAb)-based therapeutics are now standard in the treatment of cancer, and the numbers and varieties of clinically applicable mAb-based approaches continue to grow.Effective mAb-based treatments of cancer include directly targeting the cancer, altering the host response to the cancer, delivering cytotoxic moieties to the cancer and retargeting T cells towards the cancer.mAb-based treatments that directly target the cancer mediate their effects through direct signalling, antibody-dependent cellular cytotoxicity and complement-mediated lysis. Differentiating which of these mechanisms is most important for a given mAb can be difficult but is important when working to identify better mAb-based treatments.mAb-based treatments that alter the host response can alter tumour angiogenesis or the T cell response through T cell checkpoint blockade. Checkpoint-blockade mAbs are showing particular promise.mAb-based treatments that deliver cytotoxic agents to the cancer include radioimmunotherapy and antibody–drug conjugates (ADCs). ADCs are complex because of the need to match the target cancer to the right mAb, linker and drug, but early results are promising and many new ADCs are in development.mAb-based treatments that retarget T cells towards cancer include bispecific antibodies and chimeric antigen receptor T cells. Both approaches are logistically challenging but have demonstrated exciting early results, particularly in B cell malignancies.Each of these approaches has advantages and disadvantages that need to be considered in their development and evaluation.Rapid progress is taking place in the development of new agents and the testing of new approaches, both alone and in combination, in each of these areas.

oncology
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics

Ruoxuan Sun,Mark G. Qian,Xiaobin Zhang

DOI: https://doi.org/10.1080/19420862.2024.2324836

2024-03-23

mAbs

Abstract:The surge in the clinical use of therapeutic antibodies has reshaped the landscape of pharmaceutical therapy for many diseases, including rare and challenging conditions. However, the administration of exogenous biologics could potentially trigger unwanted immune responses such as generation of anti-drug antibodies (ADAs). Real-world experiences have illuminated the clear correlation between the ADA occurrence and unsatisfactory therapeutic outcomes as well as immune-related adverse events. By retrospectively examining research involving immunogenicity analysis, we noticed the growing emphasis on elucidating the immunogenic epitope profiles of antibody-based therapeutics aiming for mechanistic understanding the immunogenicity generation and, ideally, mitigating the risks. As such, we have comprehensively summarized here the progress in both experimental and computational methodologies for the characterization of T and B cell epitopes of therapeutics. Furthermore, the successful practice of epitope-driven deimmunization of biotherapeutics is exceptionally highlighted in this article.

medicine, research & experimental
Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model

Claire C Baniel,Elizabeth G Sumiec,Jacqueline A Hank,Amber M Bates,Amy K Erbe,Alexander A Pieper,Anna G Hoefges,Ravi B Patel,Alexander L Rakhmilevich,Zachary S Morris,Paul M Sondel

DOI: https://doi.org/10.1136/jitc-2020-001262

IF: 12.469

2020-10-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Some patients with cancer treated with anticancer monoclonal antibodies (mAbs) develop antidrug antibodies (ADAs) that recognize and bind the therapeutic antibody. This response may neutralize the therapeutic mAb, interfere with mAb effector function or cause toxicities. We investigated the potential influence of ADA to modify the tumor-binding capability of a tumor-reactive ‘immunocytokine’ (IC), namely, a fusion protein (hu14.18-IL2) consisting of a humanized, tumor-reactive, anti-GD2 mAb genetically linked to interleukin 2. We characterize the role of treatment delivery of IC (intravenous vs intratumoral) on the impact of ADA on therapeutic outcome following IC treatments in an established antimelanoma (MEL) regimen involving radiotherapy (RT) +IC. Methods C57BL/6 mice were injected with human IgG or the hu14.18-IL2 IC to develop a mouse anti-human antibody (MAHA) response (MAHA + ). In vitro assays were performed to assess ADA binding to IC using sera from MAHA + and MAHA − mice. In vivo experiments assessed the levels of IC bound to tumor in MAHA + and MAHA − mice, and the influence of IC route of delivery on its ability to bind to B78 (GD2+) MEL tumors. Results MAHA is inducible in C57BL/6 mice. In vitro assays show that MAHA is capable of inhibiting the binding of IC to GD2 antigen on B78 cells, resulting in impaired ADCC mediated by IC. When B78-bearing mice are injected intravenously with IC, less IC binds to B78-MEL tumors in MAHA + mice than in MAHA − mice. In contrast, when IC is injected intratumorally in tumor-bearing mice, the presence of MAHA does not detectibly impact IC binding to the tumor. Combination therapy with RT+IT-IC showed improved tumor regression compared with RT alone in MAHA + mice. If given intratumorally, IC could be safely readministered in tumor-bearing MAHA + mice, while intravenous injections of IC in MAHA + mice caused severe toxicity. Histamine levels were elevated in MAHA + mice compared with MAHA − mice after reintroduction of IC. Conclusions Intratumoral injection may be a means of overcoming ADA neutralization of therapeutic activity of tumor-reactive mAbs or ICs and may reduce systemic toxicity, which could have significant translational relevance.

oncology,immunology

Retromuscular Mesh Repair of Midline Incisional Hernia Using Polyester Standard Mesh: Monocentric Experience of 261 Consecutive Patients With a 5-Year Follow-Up

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

Monoclonal antibodies: From magic bullet to precision weapon

The role of therapeutic antibodies in drug discovery

Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy

Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework

Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations

The history of monoclonal antibody development – Progress, remaining challenges and future innovations

Drug Development of Therapeutic Monoclonal Antibodies

First aid for dentists.

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview

Opportunities and Challenges of Therapeutic Monoclonal Antibodies As Medical Countermeasures for Biodefense

Therapeutic Antibodies and Immunologic Conjugates

Monoclonal Antibodies: Emergence, Present and Outlook

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

Building better monoclonal antibody-based therapeutics

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model